Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
 
Articles by M.J. Hosseini
Total Records ( 2 ) for M.J. Hosseini
  G.R. Irajian , M. Nassaji , R. Ranjbar , A. Beheshti , R. Ghorbani , S. Salmanzadeh-Ahrabi , S. Ramazanzadeh , E. Moshiri , A. Karami , M.J. Hosseini , N. Bazzaz , N. Jonaidi Jafari and M. Izadi
  In this study, directly observed short course therapy (DOTS) was implemented to control tuberculosis in a camp in Iran. First, one study had been conducted in 1996 (before DOTS implementation) as active case finding then DOTS have been implemented in 1997. Another study was carried out in 2004 for evaluation of the effects of DOTS. In the first study, 16 patients with pulmonary TB (50% smear positive) were detected. During the years of DOTS implementation, the number of TB cases decreased significantly. In the second study, no pulmonary TB was detected. Our experience showed that DOTS significantly and effectively decreases TB in refugees and leads to a high cure rate and prevents death.
  M.J. Hosseini , R. Ranjbar , H. Ghasemi and H.R. Jalalian
  The present study was conducted to determine the prevalence of serotypes and antibiotic resistance in Shigella spp. isolated from patients admitted to Bouali hospital, Tehran, Iran during 1999 to 2001. All cases of shigellosis that were diagnosed according to their clinical pictures and microbial cultures were included in current study. Patients' age ranged from 12 to 89 years. Overall, 52 patients (56%) and 41(44%) were males and female, respectively. From a total of 90 Shigella isolates, 40 strains were identified as S. sonnei (45%), 26 as S. flexneri (27.9%), 3 as S. boydii (3%) and 21 as S. dysenteriae (24%). More than 95% of the isolates were susceptible to ciprofloxacin, ceftriaxone and ceftizoxim, 70% to nalidixic acid and less than 50% to co-trimoxazole, tetracycline, ampicillin and fourazolodon.
 
 
 
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility